

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 June 2003 (26.06.2003)

PCT

(10) International Publication Number
WO 03/051384 A1

(51) International Patent Classification⁷: **A61K 38/00, 39/00, 45/00**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,

AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(21) International Application Number: **PCT/US02/40309**

(22) International Filing Date:
17 December 2002 (17.12.2002)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/341,783 17 December 2001 (17.12.2001) US

(71) Applicant: **LUNN, Paul, G.** [US/US]; ZymoGenetics,
Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).

(72) Inventors: **CHANDRASEKHER, Yasmi, A.**; 5912 83rd
PL SE, Mercer Island, WA 98040 (US). **MCKERNAN,
Patricia, A.**; 18459 NE 196th Place, Woodinville, WA
98072 (US).

(74) Agent: **LUNN, Paul, G.**; ZymoGenetics, Inc., 1201 East-
lake Ave E, Seattle, WA 98102 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/051384 A1

[REDACTED]

A67 - 10/807,997

(54) Title: METHOD FOR TREATING CERVICAL CANCER

(57) Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus . IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.

METHOD FOR TREATING CERVICAL CANCER

5

BACKGROUND OF THE INVENTION

According to the American Cancer Society, 12,800 new cases of invasive cervical cancer would be diagnosed in the United States in 1999. During the same year, 10 4800 patients were expected to die of the disease. This represents approximately 1.8% of all cancer deaths in women and 18% of gynecological cancer deaths. However, for women aged 20 to 39 years of age, cervical cancer is the second leading cause of cancer deaths. Molecular and epidemiologic studies have demonstrated a strong relationship between human papillomavirus (HPV), cervical intraepithelial neoplasia, (CIN), and 15 invasive carcinoma of the cervix. Thus, there is a need to develop new therapeutic entities for the treatment of human papillomavirus infection, cervical intraepithelial neoplasia and carcinoma of the cervix.

DESCRIPTION OF THE INVENTION

20

The present invention fills this need by administering interleukin-20 (IL-20) to a mammalian having cervical cancer. IL-20 can also be used to treat a human papillomavirus infection. The present invention also provides a method for inhibiting the growth of cervical cancer cells by bringing IL-20 into contact with said cancerous 25 cervical cells. Interleukin-20 (formally called Zcyto10) can be produced according to the method described in International Patent Application No. PCT/US98/25228 filed on November 25 1998. The human IL-20 polypeptide is comprised of a sequence of 176 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. It is believed that amino residues 1-24 are signal sequence, and the mature IL-20 30 polypeptide is represented by the amino acid sequence comprised of residues 25, a leucine, through amino acid residue 176, a glutamic acid residue, also defined by SEQ ID NO:12. Another embodiment of the present invention is defined by the sequences of SEQ ID NO: 3 and SEQ ID NO: 4. The polypeptide of SEQ ID NO: 4 is comprised of

151 amino acid residues wherein amino acids 1-24 comprise a signal sequence and the mature sequence is comprised of amino acid residues 25, a leucine, through amino acid 151 a glutamic acid, also defined by SEQ ID NO:13. Another active variant is comprised of amino acid residues 33, a cysteine, through amino acid residue 176 of 5 SEQ ID NO:2. This variant is also defined by SEQ ID NO:26.

10 Mouse IL-20 is also a polypeptide comprised of 176 amino acid residues as defined by SEQ ID NOs: 18 and 19. Mouse IL-20 has a signal sequence extending from amino acid residue 1, a methionine, extending to and including amino acid residue 24, a glycine of SEQ ID NO:19. Thus, the mature mouse IL-20 extends from amino acid residue 25, a leucine, to and including amino acid residue 176 a leucine of SEQ ID NO:19, also defined by SEQ ID NO:20. Another active variant is believed to extend from amino acid 33, a cysteine, through amino acid 176, of SEQ ID NO:19. This variant is also defined by SEQ ID NO:25.

15 20 A variant of mouse IL-20 is defined by SEQ ID NOs: 33 and 34. This variant is 154 amino acid residues in length and has a signal sequence extending from amino acid residue 1, a methionine, to and including amino acid residue 24, a glycine, of SEQ ID NO:34. Thus, the mature sequence extends from amino acid residue 25, a leucine, to and including amino acid residue 154, a leucine, of SEQ ID NO:34. The mature sequence is also defined by SEQ ID NO:35.

Pathology of Cervical Cancer

25 Cervical dysplasia cells and cervical intraepithelial neoplasia (CIN) cells develop into invasive cervical cancer over a number of years. CIN grades I, II and III correspond to mild, moderate, and severe cervical dysplasia. CIN III, which includes severe dysplasia and carcinoma *in situ*, is unlikely to regress spontaneously and, if untreated, may eventually penetrate the basement membrane, becoming invasive carcinoma. Squamous cell carcinoma accounts for 80 to 85% of all cervical cancers; 30 adenocarcinomas account for most of the rest. Invasive cervical cancer usually spreads by direct extension into surrounding tissues and the vagina or via the lymphatics to the pelvic and para-aortic lymph nodes drained by the cervix. Hematologic spread is possible.

Symptoms, Signs and Diagnosis of Cervical Cancer

CIN is usually asymptomatic and discovered because of an abnormal Pap smear. Patients with early-stage cervical cancer usually present with irregular vaginal bleeding, which is most often postcoital, but intermenstrual bleeding or menometrorrhagia may occur. Patients with larger cervical cancers or advanced-stage disease may present with foul-smelling vaginal discharge, abnormal vaginal bleeding, or pelvic pain. Obstructive uropathy, back pain, and leg swelling are manifestations of late-stage disease. Suspicious lesions, generally first detected by a Pap smear are biopsied. If clinical disease is invasive, staging is performed on the basis of the physical examination, with a metastatic survey including cystoscopy, sigmoidoscopy, IV pyelography, chest x-ray, and skeletal x-rays.

Treatment of Cervical Cancer with IL-20

Cervical cancer can be treated by administration of IL-20 to a female mammal, particularly a human female, afflicted with the disease. IL-20 can be administered intralesionally, or intramuscularly for localized disease. For metastatic disease, IL-20 can also be administered by intraperitoneal administration including intravenous administration. IL-20 can be administered alone or in conjunction with standard therapies such as surgery, radiation or other chemotherapeutic agents such as bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

25

Use of Interleukin-20 to Treat Cells Infected with the Human Papillomavirus/Genital Warts

Cells infected with the human papillomavirus (HPV) can be treated with IL-20 to inhibit the proliferation of the virus. Anogenital warts caused by HPV type 6, 11, 16, 18, 31, 33 and 35 are transmitted sexually and have an incubation period of 1 to 6 months. Endocervical wart infections caused by type 16 or 18 have been implicated as a cause of cervical intraepithelial neoplasia and cervical cancer. HPV types 16 and 18 generally do not cause external genital warts, which are usually caused by types 6 and 11.

Symptoms, Signs and Diagnosis

Genital warts usually appear as soft, moist, minute pink or gray polyps that enlarge, may become pedunculated, and are usually found in clusters. The surfaces 5 resemble the surface of cauliflower. In men they occur most commonly on warm, moist surfaces in the subpreputial area, on the coronal sulcus, within the urethral meatus, and on the penile shaft. In women, the vulva, the vaginal wall, the cervix, and the perineum may become involved. They are particularly common in the perianal region and rectum in homosexual men. Growth rates vary, but pregnancy, immunosuppression, or 10 maceration of the skin may accelerate both the growth of individual lesions and their spread. Genital warts usually can be identified by their appearance but must be differentiated from the flat-topped condyloma lata of secondary syphilis. Biopsies of atypical or persistent warts may be necessary to exclude carcinoma.

IL-20 can be administered directly into lesions containing cells infected 15 with HPV alone or with standard therapies such as interferon alpha or interferon beta both of which are commercially available. Interferon alpha is available from Schering Corporation of Kenilworth, New Jersey and is called INTRON A®. Interferon beta is produced by Biogen of Cambridge, MA and is called AVONEX ®. IL-20 can also be administered with other standard therapies for treating HPV including antimitotics such 20 as podophyllotoxin, podophyllin, or 5-fluorouracil; caustics such as trichloroacetic acid; or interferon inducers such as imiquimod:

The quantities of IL-20 for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of 25 the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in vivo* administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Methods for administration include, 30 intravenous, peritoneal, intramuscular, or intralesional. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1 μ g to 1000 μ g per kilogram of body weight per day. However, the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art. Excipients and stabilizers can possibly be added. These 35 include glycine, histidine, glutamate, aspartate, sugars, sucrose, trehalose, galactose, sorbitol, arginine, D-and/or L-amino acids, sugar alcohols, lactose, maltose, threonine, lysine, methionine, isoleucine, a surface active agent such as TWEEN 80, TWEEN 20,

polyethylene glycol (PEG) (particularly those PEGs having molecular weights between 1000 and 35000 Da), cetyl alcohol, polyvinylpyrrolidone, polyvinyl alcohol, lanolin alcohol and sorbitan. A reducing agent may be included, such as cysteine, N-acetyl-cysteine, and thioglycerol. For a complete discussion of drug formulations and dosage ranges see *Remington's Pharmaceutical Sciences*, 18th Ed., (Mack Publishing Co., Easton, Penn., 1996), and *Goodman and Gilman's: The Pharmacological Bases of Therapeutics*, 9th Ed. (Pergamon Press 1996).

IL-20 can also be administered in conjunction with other treatments for cervical cancer such as radiation and chemotherapy. Examples of chemotherapeutic agents include bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

Example

We tested IL-20 in a HeLa299 cytotoxicity assay to measure the ability of IL-20 to prevent cells from growing during normal growth conditions. We used MTT reagent (Promega, Madison, USA) as our detection and readout for this cell inhibition assay . Procedure of a cytotoxicity assay:

Day 1- Plate cells out in complete growth media (with serum) at 5000cells/well in a 96well format and let them incubate overnight at 37degrees and 5% CO2.

Day 2- Dump off media and add a dose response of appropriate ligands in complete growth media (IL-20, zmda1, and MDA7 at 10, 100, and 1000 ng/ml.), along with a positive control retinoic acid (100uM) in complete growth media, while leaving some wells in complete growth media as controls of how the cells normally grow under normal conditions. Put the cells in incubator and let the assay go for 72hrs.

Day 5- Add 15ul/well of MTT reagent, let cells inc. for 4hrs., then add 100ul of stop solution, let cells inc. for an additional 1hr., then read the plate on a multilabel counter (Victor2, PerkinElmer Life Sciences Inc., Boston). The MTT protocol will give you two readings, one at a 650 wavelength (background) and one at a 572 wavelength. Subtract

the 650 reading from the 572 reading to get your actual output. These numbers are averaged and converted to a % inhibition value.

Results:

- 5 -Retinoic Acid gave a 53% inhibition of growth (positive control)
- IL-20 gave a maximal 20% inhibition of growth

WHAT IS CLAIMED IS:

1. A method for inhibiting the growth and or proliferation of cervical cancer cells comprising bringing Interleukin-20 (IL-20) into contact with the cervical cancer cells.
2. The method of claim 1 wherein the cervical cancer cells are treated with radiation in conjunction with IL-20.
3. The method of claim 1 wherein the cervical cancer cells are treated with one or more additional chemotherapeutic agents in conjunction with IL-20.
4. The method of claim 3 wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.
5. A method for treating a female mammal afflicted with cervical cancer comprising administering to said female mammal IL-20.
6. The method of claim 5 wherein the IL-20 is administered in conjunction with radiation.
7. The method of claim 5 wherein the IL-20 is administered in conjunction with a chemotherapeutic agent.
8. The method of claim 7 wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, chlorambucil, epirubicin, 5-fluorouracil, ifosfamide, mitomycin, methotrexate, vincristine, cisplatin and vinblastine.

9. A method for inhibiting the proliferation or growth of human papillomavirus (HPV) comprising bringing IL-20 into contact with cells infected with HPV.
10. The method of claim 9 wherein the IL-20 is injected into a genital wart infected with HPV.
11. The method of claim 9 wherein the IL-20 is administered in conjunction with the consisting of interferon alpha, interferon beta, podophyllotoxin, podophyllin and 5-fluorouracil, trichloroacetic acid, and imiquimod.
12. The method of claim 9 wherein the IL-20 is administered in conjunction with electrocauterization, laser, cryotherapy, or surgical excision of the cells infected with HPV.
13. A method for treating an individual infected with HPV comprising administering to said individual a therapeutically effective amount of IL-20.
14. The method of claim 13 wherein said individual has genital warts or lesions infected with HPV and the IL-20 is injected into the lesions or genital warts infected.
15. The method of claim 14 wherein said the IL-20 is injected into said warts in conjunction with electrocauterization, laser, cryotherapy, or surgical excision of the genital warts or lesions infected with HPV.
16. The method of claim 14 wherein the IL-20 is administered in conjunction with the consisting of interferon alpha, interferon beta, podophyllotoxin, podophyllin and 5-fluorouracil, trichloroacetic acid, and imiquimod.
17. The use of IL-20 for the production of a medicament for the treatment of cervical cancer.

18. The use of IL-20 for the production of a medicament for the treatment of human papilloma virus infection.

SEQUENCE LISTING

<110> ZymoGenetics, Inc.

<120> METHOD FOR TREATING CERVICAL CANCER

<130> 01-44PC

<150> 60/341,783
<151> 2001-12-17

<160> 43

<170> FastSEQ for Windows Version 3.0

```
<210> 1
<211> 926
<212> DNA
<213> Homo sapiens
```

<220>
<221> CDS
<222> (45) ... (572)

<400> 1

ctttaatc ctagtcctg tggctccag atttcaggcc taag atg aaa gcc tct
Met Lys Ala Ser
1

56

```

agt ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act      104
Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr
      5           10          15          20

```

cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc 152
 Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala
 25 30 35

aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cg^g ggc agt 200
 Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser
 40 45 . 50

gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act 248
 Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr
 55 60 65

gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc ctg cgc 296
 Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg
 70 75 80

cat ttg cta aga ctc tat ctg gac agg gta ttt aaa aac tac cag acc 344
 His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr
 85 90 95 100

cct gac cat tat act ctc cg ^g aag atc agc agc ctc gcc aat tcc ttt Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe 105 110 115	392
ctt acc atc aag aag gac ctc cg ^g ctc tgt cat gcc cac atg aca tgc Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala His Met Thr Cys 120 125 130	440
cat tgt ggg gag gaa gca atg aag aaa tac agc cag att ctg agt cac His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His 135 140 145	488
ttt gaa aag ctg gaa cct cag gca gca gtt gtg aag gct ttg ggg gaa Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu 150 155 160	536
cta gac att ctt ctg caa tgg atg gag gag aca gaa taggaggaaa Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu 165 170 175	582
gtgatgctgc tgctaagaat attcgagg ^t aagagctcca gtcttcaata cctgcagagg aggcatgacc ccaaaccacc atctcttac tgtactagtc ttgtgctgg ^t cacagtgtat cttatttatg cattacttgc ttcccttgc ^t gattgtcttt atgcattcccc aatcttaatt gagaccatac ttgtataaga ttttgtaat atctttctgc tattggat ^t atttatttagt taatatattt atttat ^t ttt tgctattaat gtat ^t taatt ttttacttgg gcatgaaact ttaaaaaaaaa tt ^t cacaagat tatatttata acctgactag agca	642 702 762 822 882 926
<210> 2 <211> 176 <212> PRT <213> Homo sapiens	
<400> 2 Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr 1 5 10 15 Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser 20 25 30 Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp 35 40 45 Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile 50 55 60 Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys 65 70 75 80 Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys 85 90 95 Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu 100 105 110 Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His Ala 115 120 125 His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln 130 135 140 Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys 145 150 155 160 Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu Glu Thr Glu 165 170 175	

<211> 793
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> CDS
 <222> (45)...(497)

 <400> 3
 ctttgaattc ctagctccctg tggctccag atttcaggcc taag atg aaa gcc tct 56
 Met Lys Ala Ser
 1

 agt ctt gcc ttc agc ctt ctc tct gct gcg ttt tat ctc cta tgg act 104
 Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr Leu Leu Trp Thr
 5 10 15 20

 cct tcc act gga ctg aag aca ctc aat ttg gga agc tgt gtg atc gcc 152
 Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser Cys Val Ile Ala
 25 30 35

 aca aac ctt cag gaa ata cga aat gga ttt tct gac ata cgg ggc agt 200
 Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg Gly Ser
 40 45 50

 gtg caa gcc aaa gat gga aac att gac atc aga atc tta agg agg act 248
 Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg Arg Thr
 55 60 65

 gag tct ttg caa gac aca aag cct gcg aat cga tgc tgc ctc ctg cgc 296
 Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu Leu Arg
 70 75 80

 cat ttg cta aga ctc tat ctg gac agg gta ttt aaa aac tac cag acc 344
 His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr
 85 90 95 100

 cct gac cat tat act ctc cgg aag atc agc agc ctc gcc aat tcc ttt 392
 Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe
 105 110 115

 ctt acc atc aag aag gac ctc cgg ctc tgt ctg gaa cct cag gca gca 440
 Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys Leu Glu Pro Gln Ala Ala
 120 125 130

 gtt gtg aag gct ttg ggg gaa cta gac att ctt ctg caa tgg atg gag 488
 Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met Glu
 135 140 145

 gag aca gaa taggaggaaa gtgatgctgc tgctaagaat attcgaggtc 537
 Glu Thr Glu
 150

 aagagctcca gtcttcaata cctgcagagg aggcattgacc ccaaaccacc atctctttac 597
 tgtactagtc ttgtctggt cacagtgtat ctatattatg cattactgc ttcccttgcatt 657
 gattgtcttt atgcattcccc aatcttaatt gagaccatac ttgtataaga tttttgtaat 717
 atctttctgc tattggatat atttatttagt taatatattt atttatttt tgctattaat 777

gtatttaatt ttttac

793

<210> 4
<211> 151
<212> PRT
<213> Homo sapiens

<400> 4
Met Lys Ala Ser Ser Leu Ala Phe Ser Leu Leu Ser Ala Ala Phe Tyr
1 5 10 15
Leu Leu Trp Thr Pro Ser Thr Gly Leu Lys Thr Leu Asn Leu Gly Ser
20 25 30
Cys Val Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp
35 40 45
Ile Arg Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile
50 55 60
Leu Arg Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys
65 70 75 80
Cys Leu Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys
85 90 95
Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu
100 105 110
Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys Leu Glu
115 120 125
Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu
130 135 140
Gln Trp Met Glu Glu Thr Glu
145 150

<210> 5
<211> 253
<212> DNA
<213> Homo sapiens

<400> 5
ctttgaattc ctagccctg tggctccag atttcaggcc taagatgaaa gcctctagtc 60
ttgccttcag ccttcctct gctgcgttt atctcctatg gactccttcc actggactga 120
agacactcaa ttgggaagc tggtgatcg ccacaaacct tcaggaaata cgaaatggat 180
tttctgagat acggggcagt gtgcaagcca aagatgaaaa cattgacatc agaatctaa 240
ggaggactga gtc 253

<210> 6
<211> 24
<212> DNA
<213> Homo sapiens

<400> 6
attccttagct cctgtggct ccag 24

<210> 7
<211> 25
<212> DNA
<213> Homo sapiens

<400> 7
ctctgctgcg ttttatctcc tatgg 25

<210> 8		
<211> 22		
<212> DNA		
<213> Homo sapiens		
<400> 8		
tcccaaattt agtgtttca gt		22
<210> 9		
<211> 45		
<212> DNA		
<213> Homo sapiens		
<400> 9		
cacagttcc caaaatttggat gttttcagtc cagtggagg agtcc		45
<210> 10		
<211> 747		
<212> DNA		
<213> Homo sapiens		
<400> 10		
ttttctgaca tacggggcag tttgtcaagcc aaagatggaa acattgacat cagaatctta	60	
aggaggactg agtctttgc a agacacaaaag cctgcgaatc gatgctgcct cctgcgccat	120	
ttgctaagac tctatcttgg cagggttattt aaaaactacc agacccctga ccattatact	180	
ctccggaga a tcagcagcct cgccaaattcc tttcttacca tcaagaaggaa cctccggctc	240	
tgtcatgccc acatgacatg ccattgtggg gaggaagcaa tgaagaaata cagccagatt	300	
ctgagtcact ttgaaaagct ggaaccttcag gcagcagttt tgaaggctt gggggacta	360	
gacattcttc tgcaatggat ggaggagaca gaataggagg aaagtgtgc tgctgctaag	420	
aatattcgag gtcaagagct ccagtcttca atacctgcag aggaggcatg accccaaacc	480	
accatcttct tactgtacta gtcttgcgt ggtcacatg tatcttattt atgcattact	540	
tgcttccttg catgattgtc ttatgcattt cccaaatcttta attgagacca tacttgata	600	
agatttttgt aatatcttcc tgcttattgg a tatattttt agttaatata ttatattttt	660	
ttttgctatt aatgtatttta attttttact tgggcatgaa actttaaaaaa aaattcaca	720	
gattatattt ataacctgac tagagca	747	
<210> 11		
<211> 614		
<212> DNA		
<213> Homo sapiens		
<400> 11		
ttttctgaca tacggggcag tttgtcaagcc aaagatggaa acattgacat cagaatctta	60	
aggaggactg agtctttgc a agacacaaaag cctgcgaatc gatgctgcct cctgcgccat	120	
ttgctaagac tctatcttgg cagggttattt aaaaactacc agacccctga ccattatact	180	
ctccggaga a tcagcagcct cgccaaattcc tttcttacca tcaagaaggaa cctccggctc	240	
tgtctggaa ctcaggcagc agttgtgaag gctttgggg aactagacat tcttctgcaa	300	
tggtatggagg agacacaaaata ggaggaaagt gatgctgcgt ctaagaatatt tcgaggtaa	360	
gagctccagt cttcaatacc tgcagaggag gcatgacccc aaaccacccat ctcttactg	420	
tactagtctt gtgctggcata cagtgttatct tattttatgc tttacttgctt ctttgcata	480	
ttgtctttat gcatccccaa tcttaatttga gaccatactt gtataagatt ttgtatattt	540	
ctttctgata ttggatatat ttatattgtt atatattttt ttatttttt ctattaatgt	600	
attnaattttt ttac	614	
<210> 12		
<211> 152		
<212> PRT		

<213> Homo sapiens

<400> 12

Leu	Lys	Thr	Leu	Asn	Leu	Gly	Ser	Cys	Val	Ile	Ala	Thr	Asn	Leu	Gln
1					5					10					15
Glu	Ile	Arg	Asn	Gly	Phe	Ser	Asp	Ile	Arg	Gly	Ser	Val	Gln	Ala	Lys
								20		25					30
Asp	Gly	Asn	Ile	Asp	Ile	Arg	Ile	Leu	Arg	Arg	Thr	Glu	Ser	Leu	Gln
								35		40					45
Asp	Thr	Lys	Pro	Ala	Asn	Arg	Cys	Cys	Leu	Leu	Arg	His	Leu	Leu	Arg
								50		55					60
Leu	Tyr	Leu	Asp	Arg	Val	Phe	Lys	Asn	Tyr	Gln	Thr	Pro	Asp	His	Tyr
								65		70					80
Thr	Leu	Arg	Lys	Ile	Ser	Ser	Leu	Ala	Asn	Ser	Phe	Leu	Thr	Ile	Lys
								85		90					95
Lys	Asp	Leu	Arg	Leu	Cys	His	Ala	His	Met	Thr	Cys	His	Cys	Gly	Glu
								100		105					110
Glu	Ala	Met	Lys	Lys	Tyr	Ser	Gln	Ile	Leu	Ser	His	Phe	Glu	Lys	Leu
								115		120					125
Glu	Pro	Gln	Ala	Ala	Val	Val	Lys	Ala	Leu	Gly	Glu	Leu	Asp	Ile	Leu
								130		135					140
Leu	Gln	Trp	Met	Glu	Glu	Thr	Glu								
								145		150					

<210> 13

<211> 127

<212> PRT

<213> Homo sapiens

<400> 13

Leu	Lys	Thr	Leu	Asn	Leu	Gly	Ser	Cys	Val	Ile	Ala	Thr	Asn	Leu	Gln
1					5					10					15
Glu	Ile	Arg	Asn	Gly	Phe	Ser	Asp	Ile	Arg	Gly	Ser	Val	Gln	Ala	Lys
								20		25					30
Asp	Gly	Asn	Ile	Asp	Ile	Arg	Ile	Leu	Arg	Arg	Thr	Glu	Ser	Leu	Gln
								35		40					45
Asp	Thr	Lys	Pro	Ala	Asn	Arg	Cys	Cys	Leu	Leu	Arg	His	Leu	Leu	Arg
								50		55					60
Leu	Tyr	Leu	Asp	Arg	Val	Phe	Lys	Asn	Tyr	Gln	Thr	Pro	Asp	His	Tyr
								65		70					80
Thr	Leu	Arg	Lys	Ile	Ser	Ser	Leu	Ala	Asn	Ser	Phe	Leu	Thr	Ile	Lys
								85		90					95
Lys	Asp	Leu	Arg	Leu	Cys	Leu	Glu	Pro	Gln	Ala	Ala	Val	Val	Lys	Ala
								100		105					110
Leu	Gly	Glu	Leu	Asp	Ile	Leu	Leu	Gln	Trp	Met	Glu	Glu	Thr	Glu	
								115		120					125

<210> 14

<211> 15

<212> PRT

<213> Homo sapiens

<400> 14

Ile	Ala	Thr	Asn	Leu	Gln	Glu	Ile	Arg	Asn	Gly	Phe	Ser	Asp	Ile
1					5					10				15

<210> 15

<211> 15

<212> PRT

<213> Homo sapiens

<400> 15

Leu	Asp	Arg	Val	Phe	Lys	Asn	Tyr	Gln	Thr	Pro	Asp	His	Tyr	Thr
1			5						10				15	

<210> 16

<211> 15

<212> PRT

<213> Homo sapiens

<400> 16

Leu	Ala	Asn	Ser	Phe	Leu	Thr	Ile	Lys	Lys	Asp	Leu	Arg	Leu	Cys
1				5				10				15		

<210> 17

<211> 15

<212> PRT

<213> Homo sapiens

<400> 17

Val	Val	Lys	Ala	Leu	Gly	Glu	Leu	Asp	Ile	Leu	Leu	Gln	Trp	Met
1				5				10				15		

<210> 18

<211> 824

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (71) . . . (598)

<400> 18

tgggagacat	cgatagccct	gattgatctc	tttgaatttt	cgcttctgggt	ctccaggatc	60							
taggtgttaag	atg	aaa	ggc	ttt	ggt	109							
Met	Lys	Gly	Phe	Gly	Leu	Ala	Phe	Gly	Leu	Phe	Ser	Ala	
1			5				10						

gtg	ggg	ttt	ctt	ctc	tgg	act	cct	tta	act	ggg	ctc	aag	acc	ctc	cat	157
Val	Gly	Phe	Leu	Leu	Trp	Thr	Pro	Leu	Thr	Gly	Leu	Lys	Thr	Leu	His	
15				20					25							

ttg	gga	agc	tgt	gtg	att	act	gca	aac	cta	cag	gca	ata	caa	aag	gaa	205
Leu	Gly	Ser	Cys	Val	Ile	Thr	Ala	Asn	Leu	Gln	Ala	Ile	Gln	Lys	Glu	
30				35					40				45			

ttt	tct	gag	att	cgg	gat	agt	gtg	caa	gct	gaa	gat	aca	aat	att	gac	253
Phe	Ser	Glu	Ile	Arg	Asp	Ser	Val	Gln	Ala	Glu	Asp	Thr	Asn	Ile	Asp	
50					55					60						

atc	aga	att	tta	agg	acg	act	gag	tct	ttg	aaa	gac	ata	aag	tct	ttg	301
Ile	Arg	Ile	Leu	Arg	Thr	Thr	Glu	Ser	Leu	Lys	Asp	Ile	Lys	Ser	Leu	
65					70				75							

gat agg tgc tgc ttc ctt cgt cat cta gtg aga ttc tat ctg gac agg Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg 80 85 90	349
gta ttc aaa gtc tac cag acc cct gac cac cat acc ctg aga aag atc Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile 95 100 105	397
agc agc ctc gcc aac tcc ttt ctt atc atc aag aag gac ctc tca gtc Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val 110 115 120 125	445
tgt cat tct cac atg gca tgt cat tgt ggg gaa gaa gca atg gag aaa Cys His Ser His Met Ala Cys His Cys Gly Glu Ala Met Glu Lys 130 135 140	493
tac aac caa att ctg agt cac ttc ata gag ttg gaa ctt cag gca gcg Tyr Asn Gln Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala 145 150 155	541
gtg gta aag gct ttg gga gaa cta ggc att ctt ctg aga tgg atg gag Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu 160 165 170	589
gag atg cta tagatgaaaag tggagaggct gctgagaaca ctcctgtcca Glu Met Leu 175	638
agaatctcag acctcagcac catgaagaca tggccccagg tgctggcatt tctactcaag agtcccgatc ctcagcacca cgaagatggc ctc当地accac caccctttg tgatataact tagtgcttagc tatgtgtata ttatttctac attattggct cccttatgtg aatgccttca tgtgtc	698 758 818 824
<210> 19	
<211> 176	
<212> PRT	
<213> Mus musculus	
<400> 19	
Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe 1 5 10 15	
Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser 20 25 30	
Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu 35 40 45	
Ile Arg Asp Ser Val Gln Ala Glu Asp Thr Asn Ile Asp Ile Arg Ile 50 55 60	
Leu Arg Thr Thr Glu Ser Leu Lys Asp Ile Lys Ser Leu Asp Arg Cys 65 70 75 80	
Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys 85 90 95	
Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu 100 105 110	
Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser 115 120 125	
His Met Ala Cys His Cys Gly Glu Glu Ala Met Glu Lys Tyr Asn Gln 130 135 140	

Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys
145 150 155 160
Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu
165 170 175

<210> 20
<211> 152
<212> PRT
<213> Mus musculus

<400> 20
Leu Lys Thr Leu His Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln
1 5 10 15
Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg Asp Ser Val Gln Ala Glu
20 25 30
Asp Thr Asn Ile Asp Ile Arg Ile Leu Arg Thr Thr Glu Ser Leu Lys
35 40 45
Asp Ile Lys Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu Val Arg
50 55 60
Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His
65 70 75 80
Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys
85 90 95
Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His Cys Gly Glu
100 105 110
Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser His Phe Ile Glu Leu
115 120 125
Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Gly Ile Leu
130 135 140
Leu Arg Trp Met Glu Glu Met Leu
145 150

<210> 21
<211> 16
<212> PRT
<213> Mus musculus

<400> 21
Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg
1 5 10 15

<210> 22
<211> 15
<212> PRT
<213> Mus musculus

<400> 22
Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp His His Thr
1 5 10 15

<210> 23
<211> 15
<212> PRT
<213> Mus musculus

<400> 23
Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys

1

5

10

15

<210> 24
<211> 15
<212> PRT
<213> Mus muculus

<400> 24

Val	Val	Lys	Ala	Leu	Gly	Glu	Leu	Gly	Ile	Leu	Leu	Arg	Trp	Met
1				5					10				15	

<210> 25
<211> 144
<212> PRT
<213> Mus muculus

<400> 25

Cys	Val	Ile	Thr	Ala	Asn	Leu	Gln	Ala	Ile	Gln	Lys	Glu	Phe	Ser	Glu
1					5				10				15		
Ile	Arg	Asp	Ser	Val	Gln	Ala	Glu	Asp	Thr	Asn	Ile	Asp	Ile	Arg	Ile
					20				25				30		
Leu	Arg	Thr	Thr	Glu	Ser	Leu	Lys	Asp	Ile	Lys	Ser	Leu	Asp	Arg	Cys
					35				40				45		
Cys	Phe	Leu	Arg	His	Leu	Val	Arg	Phe	Tyr	Leu	Asp	Arg	Val	Phe	Lys
					50				55				60		
Val	Tyr	Gln	Thr	Pro	Asp	His	His	Thr	Leu	Arg	Lys	Ile	Ser	Ser	Leu
					65				70				75		80
Ala	Asn	Ser	Phe	Leu	Ile	Ile	Lys	Lys	Asp	Leu	Ser	Val	Cys	His	Ser
					85				90				95		
His	Met	Ala	Cys	His	Cys	Gly	Glu	Glu	Ala	Met	Glu	Lys	Tyr	Asn	Gln
					100				105				110		
Ile	Leu	Ser	His	Phe	Ile	Glu	Leu	Glu	Leu	Gln	Ala	Ala	Val	Val	Lys
					115				120				125		
Ala	Leu	Gly	Glu	Leu	Gly	Ile	Leu	Leu	Arg	Trp	Met	Glu	Glu	Met	Leu
					130				135				140		

<210> 26

<211> 144
<212> PRT
<213> Homo sapiens

<400> 26

Cys	Val	Ile	Ala	Thr	Asn	Leu	Gln	Glu	Ile	Arg	Asn	Gly	Phe	Ser	Asp
1					5				10				15		
Ile	Arg	Gly	Ser	Val	Gln	Ala	Lys	Asp	Gly	Asn	Ile	Asp	Ile	Arg	Ile
					20				25				30		
Leu	Arg	Arg	Thr	Glu	Ser	Leu	Gln	Asp	Thr	Lys	Pro	Ala	Asn	Arg	Cys
					35				40				45		
Cys	Leu	Leu	Arg	His	Leu	Leu	Arg	Leu	Tyr	Leu	Asp	Arg	Val	Phe	Lys
					50				55				60		
Asn	Tyr	Gln	Thr	Pro	Asp	His	Tyr	Thr	Leu	Arg	Lys	Ile	Ser	Ser	Leu
					65				70				75		80
Ala	Asn	Ser	Phe	Leu	Thr	Ile	Lys	Lys	Asp	Leu	Arg	Leu	Cys	His	Ala
					85				90				95		
His	Met	Thr	Cys	His	Cys	Gly	Glu	Glu	Ala	Met	Lys	Lys	Tyr	Ser	Gln
					100				105				110		
Ile	Leu	Ser	His	Phe	Glu	Lys	Leu	Glu	Pro	Gln	Ala	Ala	Val	Val	Lys

115	120	125
Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met	Glu Glu Thr Glu	
130	135	140

<210> 27
<211> 38
<212> PRT
<213> Homo sapiens

<400> 27		
Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe		
1	5	10
Glu Lys Leu Glu Pro Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu		
20	25	30
Asp Ile Leu Leu Gln Trp		
35		

<210> 28
<211> 71
<212> PRT
<213> Homo sapiens

<400> 28		
Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg		
1	5	10
Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg		
20	25	30
Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu		
35	40	45
Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr		
50	55	60
Gln Thr Pro Asp His Tyr Thr		
65	70	

<210> 29
<211> 92
<212> PRT
<213> Homo sapiens

<400> 29		
Ile Ala Thr Asn Leu Gln Glu Ile Arg Asn Gly Phe Ser Asp Ile Arg		
1	5	10
Gly Ser Val Gln Ala Lys Asp Gly Asn Ile Asp Ile Arg Ile Leu Arg		
20	25	30
Arg Thr Glu Ser Leu Gln Asp Thr Lys Pro Ala Asn Arg Cys Cys Leu		
35	40	45
Leu Arg His Leu Leu Arg Leu Tyr Leu Asp Arg Val Phe Lys Asn Tyr		
50	55	60
Gln Thr Pro Asp His Tyr Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn		
65	70	75
Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys		80
85	90	

<210> 30
<211> 82
<212> PRT
<213> Homo sapiens

<400> 30
Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu
1 5 10 15
Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp
20 25 30
Leu Arg Leu Cys His Ala His Met Thr Cys His Cys Gly Glu Glu Ala
35 40 45
Met Lys Lys Tyr Ser Gln Ile Leu Ser His Phe Glu Lys Leu Glu Pro
50 55 60
Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln
65 70 75 80
Trp Met

<210> 31
<211> 36
<212> PRT
<213> Homo sapiens

<400> 31
Leu Asp Arg Val Phe Lys Asn Tyr Gln Thr Pro Asp His Tyr Thr Leu
1 5 10 15
Arg Lys Ile Ser Ser Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp
20 25 30
Leu Arg Leu Cys
35

<210> 32
<211> 61
<212> PRT
<213> Homo sapiens

<400> 32
Leu Ala Asn Ser Phe Leu Thr Ile Lys Lys Asp Leu Arg Leu Cys His
1 5 10 15
Ala His Met Thr Cys His Cys Gly Glu Glu Ala Met Lys Lys Tyr Ser
20 25 30
Gln Ile Leu Ser His Phe Glu Lys Leu Glu Pro Gln Ala Ala Val Val
35 40 45
Lys Ala Leu Gly Glu Leu Asp Ile Leu Leu Gln Trp Met
50 55 60

<210> 33
<211> 756
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (71)...(532)

<400> 33
tgggagacat cgatagccct gattgatctc tttgaatttt cgcttctggc ctccaggatc 60
taggtgttaag atg aaa ggc ttt ggt ctt gcc ttt gga ctg ttc tcc gct 109
Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala
1 5 10

gtg ggt ttt ctt ctc tgg act cct tta act ggg ctc aag acc ctc cat		157	
Val Gly Phe Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His			
15	20	25	
ttt gga agc tgt gtg att act gca aac cta cag gca ata caa aag gaa		205	
Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu			
30	35	40	45
ttt tct gag att cgg gat agt gtg tct ttg gat agg tgc tgc ttc ctt		253	
Phe Ser Glu Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys Phe Leu			
50	55	60	
cgt cat cta gtg aga ttc tat ctg gac agg gta ttc aaa gtc tac cag		301	
Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln			
65	70	75	
acc cct gac cac cat acc ctg aga aag atc agc agc ctc gcc aac tcc		349	
Thr Pro Asp His His Thr Leu Arg Lys Ile Ser Ser Leu Ala Asn Ser			
80	85	90	
ttt ctt atc atc aag aag gac ctc tca gtc tgt cat tct cac atg gca		397	
Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys His Ser His Met Ala			
95	100	105	
tgt cat tgt ggg gaa gaa gca atg gag aaa tac aac caa att ctg agt		445	
Cys His Cys Gly Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser			
110	115	120	125
cac ttc ata gag ttg gaa ctt cag gca gcg gtg gta aag gct ttg gga		493	
His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly			
130	135	140	
gaa cta ggc att ctt ctg aga tgg atg gag gag atg cta tagatgaaag		542	
Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu Met Leu			
145	150		
tggataggct gctgagaaca ctcctgtcca agaatctcag acctcagcac catgaagaca		602	
tggccccagg tgctggcatt tctactcaag agttccagtc ctcagcacca cgaagatggc		662	
ctcaaaccac caccctttg tgatataact tagtgtagc tatgtgtata ttatttctac		722	
attattggct cccttatgtg aatgccttca tgtg		756	
<210> 34			
<211> 154			
<212> PRT			
<213> Mus musculus			
<400> 34			
Met Lys Gly Phe Gly Leu Ala Phe Gly Leu Phe Ser Ala Val Gly Phe			
1	5	10	15
Leu Leu Trp Thr Pro Leu Thr Gly Leu Lys Thr Leu His Leu Gly Ser			
20	25	30	
Cys Val Ile Thr Ala Asn Leu Gln Ala Ile Gln Lys Glu Phe Ser Glu			
35	40	45	
Ile Arg Asp Ser Val Ser Leu Asp Arg Cys Cys Phe Leu Arg His Leu			
50	55	60	
Val Arg Phe Tyr Leu Asp Arg Val Phe Lys Val Tyr Gln Thr Pro Asp			

65	70	75	80
His His Thr Leu Arg Lys Ile Ser Ser	Leu Ala Asn Ser Phe Leu Ile		
85	90	95	
Ile Lys Lys Asp Leu Ser Val Cys His Ser His Met Ala Cys His Cys			
100	105	110	
Gly Glu Ala Met Glu Lys Tyr Asn Gln Ile Leu Ser His Phe Ile			
115	120	125	
Glu Leu Glu Leu Gln Ala Ala Val Val Lys Ala Leu Gly Glu Leu Gly			
130	135	140	
Ile Leu Leu Arg Trp Met Glu Glu Met Leu			
145	150		

<210> 35
<211> 130
<212> PRT
<213> Mus musculus

<400> 35			
Leu Lys Thr Leu His Leu Gly Ser Cys Val Ile Thr Ala Asn Leu Gln			
1	5	10	15
Ala Ile Gln Lys Glu Phe Ser Glu Ile Arg Asp Ser Val Ser Leu Asp			
20	25	30	
Arg Cys Cys Phe Leu Arg His Leu Val Arg Phe Tyr Leu Asp Arg Val			
35	40	45	
Phe Lys Val Tyr Gln Thr Pro Asp His His Thr Leu Arg Lys Ile Ser			
50	55	60	
Ser Leu Ala Asn Ser Phe Leu Ile Ile Lys Lys Asp Leu Ser Val Cys			
65	70	75	80
His Ser His Met Ala Cys His Cys Gly Glu Ala Met Glu Lys Tyr			
85	90	95	
Asn Gln Ile Leu Ser His Phe Ile Glu Leu Glu Leu Gln Ala Ala Val			
100	105	110	
Val Lys Ala Leu Gly Glu Leu Gly Ile Leu Leu Arg Trp Met Glu Glu			
115	120	125	
Met Leu			
130			

<210> 36
<211> 27
<212> DNA
<213> Homo sapiens

<400> 36
agattctatc tggacagggt attcaaa

27

<210> 37
<211> 17
<212> DNA
<213> Homo sapiens

<400> 37
gcgaggctga tcattct

17

<210> 38
<211> 25
<212> DNA
<213> Mus musculus

<400> 38	
tggcgaggct gctgatctt ctcag	25
<210> 39	
<211> 25	
<212> DNA	
<213> Mus musculus	
<400> 39	
ctttatgtct ttcaaagact cagtc	25
<210> 40	
<211> 26	
<212> DNA	
<213> Mus musculus	
<400> 40	
catcagaatt ttaaggacga ctgagt	26
<210> 41	
<211> 25	
<212> DNA	
<213> Mus musculus	
<400> 41	
ggtggtcagg ggtctggtag acttt	25
<210> 42	
<211> 23	
<212> DNA	
<213> Mus musculus	
<400> 42	
ggtgcatatt cctggggct aga	23
<210> 43	
<211> 25	
<212> DNA	
<213> Mus musculus	
<400> 43	
attgcagtgt aaggaaatac agaga	25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/40309

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00, 39/00, 45/00
 US CL : 424/85.1,198.1; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/85.1,198.1; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/03982 A1 (HUMAN GENOME SCIENCE, INC.) 28 January 1999 (28.01.1999), see entire document.	1-18
A	US 6,486,301 B1 (EBNER et al) 26 November 2002 (26.11.2002), see entire document.	1-18
A	BLUMBERG et al. Interleukin 20: Discovery, Receptor Identification, and Role in Epidermal Function. Cell. 12 January 2001, Vol. 104, No. 1, pages 9-19, see entire document.	1-18

 Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 April 2003 (02.04.2003)

Date of mailing of the international search report

22 APR 2003

Name and mailing address of the ISA/US

 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Stella O. Roberts for
Christopher Yaen

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/40309

Continuation of B. FIELDS SEARCHED Item 3:
STN DATABASE, MEDLINE, CANCERLIT, BIOSIS, CONFSCI, CAPLUS, EMBASE, SCISEARCH, USPATFULL, PCTFULL

THIS PAGE BLANK (USPTO)